RAF Proto Oncogene Serine/Threonine Protein Kinase-Pipeline Review H2 2017
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)-Pipeline Review, H2 2017
(EMAILWIRE.COM, September 28, 2017 ) According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase-Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)-RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
Request Sample Report@ http://www.reportsweb.com/inquiry&RW00011030805/sample
The report 'RAF Proto Oncogene SerineThreonine Protein Kinase-Pipeline Review, H2 2017' outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Adenocarcinoma, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.
Inquiry for Buying@ http://www.reportsweb.com/inquiry&RW00011030805/buying
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Amitech Therapeutic Solutions Inc, H2 2017
Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pipeline by CBT Pharmaceuticals Inc, H2 2017
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Redx Pharma Plc, H2 2017
Pipeline by VG Life Sciences Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Get Discount@ http://www.reportsweb.com/inquiry&RW00011030805/discount
List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administrations, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)-RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
Request Sample Report@ http://www.reportsweb.com/inquiry&RW00011030805/sample
The report 'RAF Proto Oncogene SerineThreonine Protein Kinase-Pipeline Review, H2 2017' outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Adenocarcinoma, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.
Inquiry for Buying@ http://www.reportsweb.com/inquiry&RW00011030805/buying
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Amitech Therapeutic Solutions Inc, H2 2017
Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pipeline by CBT Pharmaceuticals Inc, H2 2017
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Redx Pharma Plc, H2 2017
Pipeline by VG Life Sciences Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Get Discount@ http://www.reportsweb.com/inquiry&RW00011030805/discount
List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administrations, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results